Beyond peroxisome proliferator-activated receptor \( \gamma \) signaling: the multi-facets of the antitumor effect of thiazolidinediones

J-R Weng\(^1,2\), C-Y Chen\(^3,4\), J J Pinzone\(^5\), M D Ringel\(^5\) and C-S Chen\(^6\)

\(^1\)Department of Biological Science and Technology, China Medical University, Taichung 404, Taiwan  
\(^2\)China Medical University Hospital, Taichung 404, Taiwan  
\(^3\)Department of Family Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan  
\(^4\)Division of Gerontology Research, National Health Research Institutes, Taipei, Taiwan  
\(^5\)Divisions of Endocrinology and Oncology, Department of Internal Medicine and \(^6\)Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Parks Hall, Ohio State University, 500 West 12th Avenue, Columbus, Ohio 43210, USA

Requests for offprints should be addressed to C-S Chen; Email: chen.844@osu.edu

Abstract

Certain members of the thiazolidinedione (TZD) family of the peroxisome proliferator-activated receptor \( \gamma \) (PPAR\( \gamma \)) agonists, such as troglitazone and ciglitazone, exhibit antitumor activities; however, the underlying mechanism remains inconclusive. Substantial evidence suggests that the antiproliferative effect of these TZD members in cancer cells is independent of PPAR\( \gamma \) activation. To discern the role of PPAR\( \gamma \) in the antitumor effects of TZDs, we have synthesized PPAR\( \gamma \)-inactive TZD analogs which, although devoid of PPAR\( \gamma \) activity, retain the ability to induce apoptosis with a potency equal to that of their parental TZDs in cancer cell lines with varying PPAR\( \gamma \) expression status. Mechanistic studies from this and other laboratories have further suggested that troglitazone and ciglitazone mediate antiproliferative effects through a complexity of PPAR\( \gamma \)-independent mechanisms. Evidence indicates that troglitazone and ciglitazone block BH3 domain-mediated interactions between the anti apoptotic Bcl-2 (B-cell leukemia/lymphoma 2) members Bcl-2/Bcl-xL and proapoptotic Bcl-2 members. Moreover, these TZDs facilitate the degradation of cyclin D1 and caspase-8-related FADD-like IL1-converting enzyme (FLICE)-inhibitory protein through proteasome-mediated proteolysis, and down-regulate the gene expression of prostate-specific antigen gene expression by inhibiting androgen activation of the androgen response elements in the promoter region. More importantly, dissociation of the effects of TZDs on apoptosis from their original pharmacological activity (i.e. PPAR\( \gamma \) activation) provides a molecular basis for the exploitation of these compounds to develop different types of molecularly targeted anticancer agents. These TZD-derived novel therapeutic agents, alone or in combination with other anticancer drugs, have translational relevance in fostering effective strategies for cancer treatment.

Introduction

Thiazolidinediones (TZDs), including troglitazone (Rezulin), rosiglitazone (Avandia), pioglitazone (Actos), and ciglitazone, are synthetic ligands for the peroxisome proliferator-activated receptor \( \gamma \) (PPAR\( \gamma \)) (for review see Day 1999) (Fig. 1). This family of PPAR\( \gamma \) agonists improves insulin sensitivity by increasing transcription of certain insulin-sensitive genes involved in the metabolism and transport of lipids in adipocytes, such as lipoprotein lipase, adipocyte fatty acid-binding protein, acyl-CoA synthase, and fatty acid transport protein (Koeffler 2003). In addition, TZDs have been demonstrated to promote the differentiation of preadipocytes by mimicking certain genomic effects of insulin on adipocytes (Tontonoz et al. 1994), and to regulate glucose homeostasis (Saltiel & Olefsky 1996). Consequently, the TZDs offer a new type of oral therapy in type II diabetes to reduce insulin resistance and to assist glycemic control.

Recent evidence indicates that certain TZD members, especially troglitazone and ciglitazone, exhibit moderate antiproliferative activities against
The TZD family of PPARγ agonists and PPARγ-inactive TZDs

![Chemical structures of troglitazone, ciglitazone, rosiglitazone, and pioglitazone, and their respective PPARγ-inactive Δ2 derivatives (Δ2-TG, Δ2-CG, Δ2-RG, and Δ2-PG).](image)

The introduction of the double bond adjoining the terminal thiazolidinedione ring results in the abrogation of the PPARγ ligand property.

many epithelial-derived human cancer cell lines including those of prostate (Kubota et al. 1998), breast (Yin et al. 2001), colon (Kato et al. 2004), thyroid (Ohta et al. 2000), and pituitary carcinoma (Heaney et al. 2003). This growth inhibition was linked to the G1 phase cell cycle arrest through the up-expression of the cyclin-dependent kinase inhibitors p21 and p27 (Koga et al. 2001, 2003, Takeuchi et al. 2002, Yoshizawa et al. 2002, Bae et al. 2003) and/or repression of cyclin D1 expression (Wang et al. 2001, Yin et al. 2001, Lapillonne et al. 2003, Qin et al. 2003). Meanwhile, data from this and other laboratories have indicated that normal prostate epithelial cells (not shown) and T lymphocytes (Harris & Phipps 2002) are more resistant to apoptotic induction by these TZDs. In the light of this cancer-specific effect, the potential use of these PPARγ agonists as chemopreventive agents has received much attention (for a review see Badawi & Badr 2002, Kopelovich et al. 2002, Smith & Kantoff 2002, Bull 2003, Koeffler 2003, Leibowitz & Kantoff 2003, Grommes et al. 2004, Jiang et al. 2004). Moreover, animal model studies have demonstrated the in vivo efficacy of troglitazone in colon, prostate, and liver cancers (Kubota et al. 1998, Sarraf et al. 1998, Yu et al. 2006) and that of rosiglitazone in pituitary tumors (Henry et al. 2000, Heaney et al. 2002). Despite these advances, the mechanism underlying the antitumor effects of TZD remains unclear. As PPARγ-mediated effects of TZDs promote the differentiation of preadipocytes, one school of thought attributes the same mechanism to the terminal differentiation and cell cycle arrest of tumor cells (Tontonoz et al. 1997). However, the PPARγ-target genes that mediate the antiproliferative effects remain elusive, as genomic responses to PPARγ activation in cancer cells are highly complicated (Gupta et al. 2001). Reported causal mechanisms include attenuated expression of protein phosphatase 2A (Altiok et al. 1997), cyclins D1 and E, inflammatory cytokines and transcription factors (Koeffler 2003), and increased expression of an array of gene products linked to growth regulation and cell maturation (Gupta et al. 2001).

On the other hand, several lines of evidence have suggested that the inhibitory effect of TZDs on tumor cell proliferation is independent of PPARγ activation. For example, sensitivity of cancer cells to TZD-induced growth inhibition does not correlate with the level of PPARγ expression, and there exists a three orders of magnitude discrepancy between the concentration required to produce antitumor effects and that to modify insulin action (Day 1999). In addition, the in vitro antitumor effects appear to be structure specific irrespective of their potency in PPARγ activation, i.e. troglitazone and ciglitazone are active while rosiglitazone and pioglitazone are not. To date, an array of non-PPARγ targets has been implicated in the antitumor activities of troglitazone and/or ciglitazone in different cell systems, which include intracellular Ca2+ stores (Palakurthi et al. 2001), phosphorylating activation of extracellular signal-regulated kinases (Gouni-Berthold et al. 2001, Takeda et al. 2001), c-Jun N-terminal protein kinase, and p38 (Bae & Song 2003), up-regulation of early growth response-1 (Baek et al. 2003), the cyclin-dependent kinase (CDK) inhibitors p27kip1 (Motomura et al. 2000) and p21WAF1/CIP1 (Sugimura et al. 1999), the tumor suppressor protein p53 and the p53-responsive stress protein Gadd45 (Okura et al. 2001), and altered expression of B-cell leukemia/lymphoma 2 (Bcl-2) family members (Baie & Song 2003). However, some of these targets appear to be cell type specific due to differences in signaling pathways regulating cell growth and survival in different cell systems.

In considering the translational potential of using PPARγ ligand in cancer prevention and therapy, our research has focused on elucidating the mechanisms underlying the antitumor effect of TZDs. In the following sections, evidence that dissociates the effect of TZDs on apoptosis from PPARγ-activating activity is presented. This review also provides an
overview of recent findings from this and other laboratories concerning plausible PPARγ-independent targets that underlie TZD-mediated apoptosis. Equally importantly, the use of TZDs as a molecular platform to develop novel mechanism-based therapeutic agents will be discussed.

Demonstration of PPAR-independent antiproliferative effects of TZDs

We hypothesized that if TZDs mediate antitumor effects independently of PPARγ, one would be able to dissociate these two pharmacological activities via structural modifications of these molecules. This premise was corroborated by the development of a novel class of PPARγ-inactive TZD analogs, which was accomplished by introducing a double bond adjoining the terminal thiazolidine-2,4-dione ring (Fig. 1) (Shiau et al. 2005). Two lines of evidence indicate that this structural modification abrogated the ligand-binding ability of PPARγ. First, these Δ2 analogs (5-[4-(6-hydroxy-2,5,7,8-tetramethyl-chroman-2-yl-methoxy)-benzyldiene]-2,4-thiazolidinedione (Δ2-TG), 5-[4-[2-(methyl-pyridin-2-yl-amino)-ethoxy]-benzyldiene]-2,4-thiazolidinedione (Δ2-RG), 5-[4-[2-(5-ethyl-pyridin-2-yl)-ethoxy]-benzyldiene]-2,4-thiazolidinedione (Δ2-PG), and 5-[4-(1-methyl-cyclohexylmethoxy)-benzyldiene]-thiazolidinedione-2,4-dione (Δ2-CG)) were inactive in PPARγ activation according to a PPARγ transcription factor ELISA (Shiau et al. 2005). Secondly, DU-145 prostate cancer cells were transfected with a reporter construct that contains PPAR response element (PPRE) upstream of a luciferase gene. None of these Δ2 derivatives elicited any significant PPARγ transactivation. The loss of PPARγ activity was presumably attributed to the structural rigidity, as a result of the double bond introduction surrounding the heterocyclic system.

These PPARγ-inactive TZD derivatives were examined in two prostate cancer cell lines with distinct PPARγ expression status, androgen-independent PC-3 and androgen-dependent LNCaP. Between these two cell lines, PPARγ was highly expressed in PC-3 cells, but was deficient in LNCaP cells (Fig. 2A). Nevertheless, despite a deficiency in PPARγ, LNCaP cells exhibited a higher degree of susceptibility to troglitazone-mediated in vitro antitumor effects compared with the PPARγ-rich PC-3 cells (Fig. 2B, left panel). In addition, Δ2-TG, although devoid of PPARγ-activating activity, was more potent than troglitazone in suppressing cell proliferation in both cell lines. This growth inhibition was attributable to apoptotic death, as evidenced by mitochondrial cytochrome c release in PC-3 cell (Fig. 2B, right panel).

Similar results were obtained with ciglitazone and Δ2-CG with respect to cytochrome c-dependent apoptotic death in PC-3 cells (Fig. 3), with relative potency similar to that of troglitazone and Δ2-TG. In contrast, rosiglitazone, pioglitazone, and their Δ2 derivatives showed marginal effects, even at 50 μM, on cell death in PC-3 cells (Fig. 3).

Together, these data suggest that TZDs mediated apoptosis induction in prostate cancer cell systems irrespective of PPARγ activation. Mechanistic studies from this and other laboratories have further suggested that TZDs mediate proapoptotic effects through a complexity of PPARγ-independent molecular targets, which include, but are not limited to, Bcl-2/Bcl-xL, cyclin D1, FADD-like IL-1-converting enzyme (FLICE)-inhibitory protein (FLIP), and prostate specific antigen (PSA), which are summarized as follows.

TZD-induced apoptosis involves the inhibition of Bcl-xL and Bcl-2 function

The functional relationship between antiapoptotic and proapoptotic Bcl-2 members in the regulation of mitochondrial integrity is well documented (Cory et al. 2003). Bcl-2 and Bcl-xL mediate their antiapoptotic function through the sequestration of Bad, Bax, and other proapoptotic Bcl-2 members via BH3 domain-facilitated heterodimerization, thereby abrogating their ability to induce mitochondrial cytochrome c release (Diaz et al. 1997, Sattler et al. 1998, Otter et al. 1998, Nouraini et al. 2000, Finnegan et al. 2001). Thus, a balance between these two types of Bcl-2 members plays a crucial role in the regulation of the apoptotic machinery.

Effect of troglitazone on the expression of Bcl-2 family members

It has been reported that troglitazone at high doses repressed Bcl-2 expression in MCF-7 breast cancer (Elstner et al. 1998), and increased the expression level of the proapoptotic proteins Bad and Bax in HepG2 hepatoma cells (Bae & Song 2003). This phenomenon, however, appears to be cell line specific. In our study, troglitazone, even at 30 μM, did not cause appreciable changes in the expression of any of the aforementioned Bcl-2 members in PC-3 cells with the exception of a slight decrease in Bad expression at 24-h exposure (Fig. 4) (Shiau et al. 2005).
Figure 2  Evidence that the effect of troglitazone on apoptosis in prostate cancer cells is dissociated from PPARγ activation. (A) Western blot analysis of relative PPARγ levels in PC-3 and LNCaP prostate cancer cells. (B, left panels) Dose-dependent effects of troglitazone and Δ2-TG on the cell viability of PC-3 and LNCaP cells in serum-free RPMI 1640 medium for 24 h. Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay; (right panels) levels of cytochrome c release into cytoplasm induced by different doses of troglitazone and Δ2-TG in PC-3 cells under the aforementioned treatment conditions. Values are means ± s.d. *, P < 0.05.

Figure 3  Differential effects of ciglitazone, rosiglitazone, pioglitazone, and their Δ2 derivatives on apoptotic death in PC-3 cells in serum-free RPMI 1640 medium for 24 h. Values are means ± s.d.
Inhibition of Bcl-xL and Bcl-2 function

Nevertheless, we obtained several lines of evidence that troglitazone and ciglitazone might inhibit the antiapoptotic function of Bcl-xL/Bcl-2 by blocking BH3 domain-mediated heterodimerization with pro-apoptotic Bcl-2 members (Shiau et al. 2005). First, data from the competitive fluorescence polarization analysis suggest that troglitazone, ciglitazone, and their \( \text{C}1 \) counterparts compete with a Bak BH3-domain peptide for binding to Bcl-xL and Bcl-2. Moreover, the potency of TZDs and their \( \text{C}1 \) analogs in inhibiting this peptide binding correlated with the respective effectiveness in inducing apoptotic death in LNCaP and PC-3 prostate cancer cells (Table 1).

For example, the inability of rosiglitazone and pioglitazone to trigger apoptotic death was reflected in their lack of potency in disrupting interactions between Bcl-xL/Bcl-2 and the Bak BH3 domain. Secondly, troglitazone and \( \Delta2 \)-TG perturbed the dynamics of intracellular Bcl-2/Bak and Bcl-xL/Bak interactions in PC-3 cells, i.e. the level of Bak associated with Bcl-2 and Bcl-xL was greatly reduced in troglitazone- and \( \Delta2 \)-TG-treated cells as compared with DMSO control (Fig. 5A). As a result, liberation of proapoptotic Bcl-2 members induced apoptosis by facilitating cytochrome c release and consequent caspase-9 activation (Fig. 5B).

Thirdly, overexpression of Bcl-xL provided LNCaP cells conferred protection against troglitazone- and \( \Delta2 \)-TG-induced apoptosis. As shown in Fig. 5C, ascending expression levels of Bcl-xL in three transfected LNCaP stable clones (B11, B1, and B3) diminished the susceptibility to troglitazone- and \( \Delta2 \)-TG-induced apoptosis death as compared with that of parental LNCaP cells. The extent of cytoprotection conferred by ectopic Bcl-xL correlated with the Bcl-xL expression level. The excessive expression in B3 cells especially completely overcame the apoptotic effect of troglitazone and \( \Delta2 \)-TG.

Antiproliferative mechanisms involve modulation of cell cycle effectors

Troglitazone and ciglitazone repress cyclin D1 expression via proteasome-facilitated proteolysis

PPAR\( \gamma \) agonists, including 15-deoxy-\( \Delta 12,14 \)-prostaglandin \( J_2 \) (PGJ\( _2 \)), troglitazone, and ciglitazone, at high doses, have been shown to down-regulate cyclin D1 expression as part of their action to cause cell-cycle arrest and growth inhibition in breast cancer cells (Wang et al. 2001, Yin et al. 2001, Lapillonne et al. 2003, Qin et al. 2003, 2004, Huang et al. 2005). Cyclin D1 is a downstream effector of diverse proliferative and transforming signaling pathways, including those mediated by \( \beta \)-catenin (Shtutman et al. 1999), estrogen receptor

Table 1 Correlation between the IC\( _{50} \) values of individual TZDs and \( \Delta2 \)-TZDs for inhibiting BH3-mediated interactions of Bcl-xL and Bcl-2 with the Bak BH3 domain peptide and for inhibiting cell proliferation of PC-3 and LNCaP prostate cancer cells. Values are means \( \pm \) S.D.

<table>
<thead>
<tr>
<th></th>
<th>TG</th>
<th>( \Delta2 )-TG</th>
<th>CG</th>
<th>( \Delta2 )-CG</th>
<th>RG</th>
<th>( \Delta2 )-RG</th>
<th>PG</th>
<th>( \Delta2 )-PG</th>
</tr>
</thead>
<tbody>
<tr>
<td>IC( _{50} ) in binding inhibition (( \mu M ))(^1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bcl-xL</td>
<td>22 ( \pm ) 1</td>
<td>18 ( \pm ) 1</td>
<td>26 ( \pm ) 2</td>
<td>17 ( \pm ) 2</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td>&gt;50</td>
</tr>
<tr>
<td>Bcl-2</td>
<td>22 ( \pm ) 1</td>
<td>18 ( \pm ) 1</td>
<td>24 ( \pm ) 3</td>
<td>22 ( \pm ) 3</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td>&gt;50</td>
</tr>
<tr>
<td>IC( _{50} ) in cell viability inhibition (M)(^2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PC-3</td>
<td>30 ( \pm ) 2</td>
<td>20 ( \pm ) 2</td>
<td>22 ( \pm ) 4</td>
<td>14 ( \pm ) 1</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td>&gt;50</td>
</tr>
<tr>
<td>LN-CaP</td>
<td>22 ( \pm ) 3</td>
<td>14 ( \pm ) 1</td>
<td>n.d.</td>
<td>n.d.</td>
<td>n.d.</td>
<td>n.d.</td>
<td>n.d.</td>
<td>n.d.</td>
</tr>
</tbody>
</table>

\(^1\) Determined by fluorescence polarization analysis of the ability of individual compounds to inhibit the binding of the Flu-BakBH3 peptide with Bcl-xL or Bcl-2.

\(^2\) Determined by the MTT assay.

n.d., not determined.
(ER) (Lukas et al. 1996, Wilcken et al. 1997, Prall et al. 1998), Her-2/Neu (Lee et al. 2000), nuclear factor-kB (Joyce et al. 1999, Henry et al. 2000), Rac (Westwick et al. 1997), Ras (Albanese et al. 1995), Src (Lee et al. 1999), signal transducer and activator of transcription (Bromberg et al. 1999, Matsumura et al. 1999), and Wnt (D’Amico et al. 2000). In mammary cells, transcriptional activation of cyclin D1 in response to these mitogenic signals leads to G1/S progression and increased proliferation. Cyclin D1 overexpression has been implicated in oncogene-induced mammary tumorigenesis; it has been noted that more than 50% of primary breast carcinomas correlated with poor prognosis (McIntosh et al. 1995, Kenny et al. 1999). In addition to activating cyclin-dependent kinases (CDKs) and sequestering CDK inhibitors in the G1/S transition, the function of cyclin D1 as a CDK-independent activator of ERα is especially noteworthy (Neuman et al. 1997, Zwijsen et al. 1997, McMahon et al. 1999, Lamb et al. 2000). Cyclin D1 overexpression confers resistance to antiestrogens in breast cancer cells (Musgrove et al. 2001, Hui et al. 2002), and represents a negative predictive factor for tamoxifen response (Stendahl et al. 2004). Together, these findings suggest that an anti-cyclin D1 therapy might be highly specific for treating human breast cancer (Yu et al. 2001). An urgent

Figure 5  Troglitazone (TG) and Δ2-TG trigger caspase-dependent apoptotic death by inhibiting heterodimer formation of Bcl-2 and Bcl-xL with Bak. (A) Effect of TG and Δ2-TG on the dynamics of Bcl-2/Bak (left) and Bcl-xL/Bax (right) interactions in PC-3 cells. PC-3 cells were treated with 50 μM TG or Δ2-TG for 12 h, and cell lysates were immunoprecipitated with anti-Bcl-2 or anti-Bcl-xL antibodies. The immunoprecipitates were probed with anti-Bak antibodies by western blot analysis (WB). The bar graphs indicate the relative Bak levels, normalized to IgG light chain levels, in the three treatments. Values are means ± s.d. (n = 3). *P < 0.01. (B) Dose-dependent effect of TG and Δ2-TG on caspase-9 activation in PC-3 cells. PC-3 cells were treated with TG or Δ2-TG at the indicated concentrations for 24 h. Caspase-9 antibodies recognize the large subunits (35 and 37 kDa). (C) Ectopic Bcl-xL protects LNCaP cells from TG- and Δ2-TG-induced apoptosis by attenuating cytochrome c release in an expression level-dependent manner. (Left panel) Ascending expression levels of ectopic Bcl-xL in B11, B1, and B3 clones by western blot analysis. (Right panel) Dose-dependent effects of TG (left panel) and Δ2-TG (right panel) on apoptosis in LNCaP, B11, B1, and B3 cells. Data are means ± s.d. (n = 3).
need therefore exists to develop potent cyclin D1-ablative agents that are effective in the therapeutically attainable range (≤5 μM) for breast cancer prevention and/or therapy.

As troglitazone provides an attractive starting point for this drug discovery effort, the mechanism underlying its effect on cyclin D1 repression constituted the focus of our recent investigation (Huang et al. 2005). Several lines of evidence suggest that troglitazone mediates the repression of cyclin D1 expression via a PPARγ-independent mechanism. First, Δ2-TG and Δ2-CG, although devoid of PPARγ activity, were able to mediate cyclin D1 ablation with slightly higher potency than troglitazone and ciglitazone respectively in MCF-7 breast cancer cells (Fig. 6A), while the more potent PPARγ agonists rosiglitazone and pioglitazone lacked appreciable activity at comparable concentrations (not shown).

Secondly, troglitazone-mediated cyclin D1 down-regulation could not be rescued by the PPARγ antagonist 2-chloro-5-nitro-N-phenylbenzamide (GW9662). Thirdly, despite significantly higher PPARγ expression, MDA-MB-231 breast cancer cells were less susceptible to troglitazone-induced cyclin D1 ablation than MCF-7 cells. Although it has been reported that the PPARγ ligands PGJ2 and troglitazone inhibited cyclin D1 transcription by activating PPARγ in MCF-7 cells (Wang et al. 2001) and mouse skin keratinocytes (He et al. 2004) respectively, data from this and other laboratories have indicated that troglitazone and ciglitazone mediate cyclin D1 ablation in MCF-7 cells by facilitating ubiquitination and proteasomal

Figure 6 Pharmacological evidence that the effect of troglitazone and ciglitazone on cyclin D1 down-regulation in MCF-7 cells is dissociated from PPARγ activation. (A) Dose-dependent effect of troglitazone and Δ2-TG on cyclin D1 expression for 24 h in MCF-7 cells by western blotting. (B) Dose-dependent effects of troglitazone on the expression of cyclins and CDKs in MCF-7 cells by western blot analysis.
proteolysis in a specific manner (Qin et al. 2003, Huang et al. 2005). For example, PCR analysis indicates that the mRNA level of cyclin D1 remained unaltered in drug-treated cells, indicating that the repression was mediated at the post-transcriptional level. Moreover, this drug-induced cyclin D1 repression could be rescued by proteasome inhibitors, and was preceded by increased ubiquitination.

It is noteworthy that the troglitazone-mediated cyclin D1 ablation was highly specific. Among all cyclins and CDKs examined (cyclins D2, D3, A, B, and E, and CDKs 2 and 4) as well as p53, only cyclin D2 and CDK4 showed a slight decrease in the expression level in drug-treated MCF-7 cells (Fig. 6B). Moreover, western blotting analysis indicates that, in MCF-7 cells, troglitazone up-regulated the expression of p21CIP1, while p27KIP1 exhibited a dose-dependent decrease (Fig. 6B) (Huang et al. 2005). However, the effect of troglitazone on the expression levels of these two CDK inhibitors varies among different cell lines. For example, troglitazone treatment led to increased expression of both p21CIP1 and p27KIP1 in several hepatocellular carcinoma cells examined (El nemr et al. 2000, Koga et al. 2001), while in troglitazone-treated pancreatic cancer cells, only the expression level of p27KIP1, but not that of p21CIP1, increased (Motomura et al. 2000, Itami et al. 2001). These findings suggested that variations in responses exist among different cancer cell lines.

**Other molecular mechanisms**

In addition to the aforementioned effects, several other PPARγ-independent mechanisms have been reported to account for the antiproliferative action of TZDs in different cancer cells. Among these proposed mechanisms, the effects on proteasome-mediated degradation of FLIP (Kim et al. 2002) and down-regulation of PSA expression (Kubota et al. 1998, Hisatake et al. 2000) are especially noteworthy in light of their clinical implications in cancer therapy.

FLIP inhibits apoptosis induced by tumor necrosis factor (TNF) family death receptor by blocking caspase 8 activation (Wajant 2003). As demonstrated by antisense-mediated down-regulation, decreased expression of FLIP confers sensitivity against death receptor-induced apoptosis. Inhibition of FLIP expression in tumor cells is of particular importance to TNF-related apoptosis inducing ligand (TRAIL)-based cancer therapy (Wajant 2003). TRAIL is the ligand of death receptors, and has attracted substantial clinical interests in light of its ability to induce apoptosis preferentially in tumor cells. However, not all tumor cells respond to TRAIL, in part because of intracellular resistance mechanisms (Ashkenazi 2002). Recent reports indicate that PPARγ agonists including troglitazone could sensitize tumor cells to TRAIL-induced apoptosis (Go ke et al. 2000, Kim et al. 2002) as a result of the proteasome-dependent proteolysis of FLIP (Kim et al. 2002). As the mode of FLIP down-regulation is reminiscent of that of cyclin D1, there may exist cross-reactivity in troglitazone-mediated proteasomal degradation of both proteins.

PSA is used as a serum biomarker for diagnosis and progression of prostate cancer (Polascik et al. 1999). It has been shown that troglitazone at concentrations (≤10μM) lower than that required for growth inhibition (≥20μM) was able to down-regulate PSA expression in LNCaP prostate cancer cells through the inhibition of androgen activation of the androgen response elements in the regulatory region of the PSA gene (Hisatake et al. 2000). Moreover, the same report indicates that troglitazone at 600–800 mg/day stabilized PSA levels in a prostate cancer patient with a radical prostectomy throughout a 14-month period.

**Pharmacological exploitation of troglitazone to develop novel mechanism-based anticancer agents**

The above discussion clearly demonstrates that the antiproliferative activity of troglitazone is mediated through multiple molecular targets independently of PPARγ. From a mechanistic perspective, dissociation of the aforementioned pharmacological activities from PPARγ activation provide a molecular rationale to use troglitazone as a starting point to develop novel mechanism-based therapeutic agents. The proof of the principle of this premise is 5-[4-(6-allyoxy-2,5,7,8-tetramethyl-chroman-2-yl-methoxy)-benzylidene]-2,4-thiazolidinedione (Δ2-TG-6) (Huang et al. 2005), a close structural analog that exhibited an order of magnitude higher potency than troglitazone and Δ2-TG in repressing cyclin D1 expression and inhibiting MCF-7 cell proliferation (Fig. 7).
As shown, Δ2-TG-6 reduced cyclin D1 levels at concentrations as low as 2.5 μM compared with ≥20 μM for Δ2-TG (Fig. 7B), and exhibited IC_{50} of 8 μM versus 55 μM for Δ2-TG in inhibiting MCF-7 cell viability (Fig. 7C). This antiproliferative effect was attributable to apoptosis induction, as evidenced by poly(ADP-ribose)polymerase (PARP) cleavage (Fig. 7D). Lead optimization of Δ2-TG-6 to generate more potent cyclin D1-ablative agents is currently undergoing, the clinical implication of which is multifold. First, cyclin D1 ablation provides specific protection against breast carcinogenesis (Yu et al. 2001). Secondly, in light of the role of cyclin D1 overexpression in antiestrogen resistance, cyclin D1 ablation may help overcome the resistance. Thirdly, the synergistic interaction between flavopiridol and trastuzumab in inhibiting breast cancer cell proliferation is attributable, in part, to the reduction of cyclin D1 expression (Wu et al. 2002). These agents may sensitize cells to the antiproliferative action of either CDK inhibition or Her-2/Akt inhibition.

A similar approach has been taken to develop a potent Bcl-2/Bcl-xL inhibitor (TG-88) with an IC_{50} of 1.8 μM based on fluorescence polarization analysis. Oral TG-88 at a daily dose of 100 or 200 mg/kg was effective in suppressing PC-3 xenograft tumor growth without causing weight loss or apparent toxicity, indicating its oral bioavailability and potential clinical use (Shiau et al. 2005). It is also noteworthy that the structural requirement for Bcl-2/Bcl-xL inhibition differed from that of cyclin D1 ablation.

**Conclusion**

Data from this and other laboratories have clearly demonstrated that the effect of TZDs on triggering apoptosis in cancer cells is dissociated from that of PPARγ activation. To date, a number of important signaling mechanisms have been identified to underlie TZD-mediated antitumor activities, including, but not limited to, inhibition of Bcl-2/Bcl-xL function and repression of the expression of cyclin D1, FLIP, and PSA. These findings provide molecular underpinnings for the molecular exploitation of troglitazone and ciglitazone to develop different types of molecularly targeted anticancer agents. Our data indicate that structural preference for Bcl-2/Bcl-xL inhibition differs from that of cyclin D1 ablation, while that between cyclin D1 and FLIP is currently being investigated. Because of the heterogeneity in the cancer cell population, various genetic lesions/molecular defects allow different subsets of tumor cells to exhibit differential sensitivity to apoptotic signals generated by different chemotherapeutic agents. Thus, these troglitazone-derived agents in combination with other therapeutic agents have translational relevance in fostering effective strategies for cancer treatment.
Acknowledgements

This work was supported by Public Health Service Grants CA-94829 and CA-112250 (C-S C), and K08CA101875 (JJ P) from National Cancer Institute, NIH, Department of Health and Human Service, and by Army Grant W81XWH-05-1-0089 from Department of Defense Prostate Cancer Research Program (C-S C). The authors declare that there is no conflict of interest that would prejudice the impartiality of this scientific work.

References


Bae MA, Rhee H & Song BJ 2003 Troglitazone but not rosiglitazone induces G1 cell cycle arrest and apoptosis in human and rat hepatoma cell lines. Toxicology Letters 139 67–75.


Jiang M, Shappell SB & Hayward SW 2004 Approaches to understanding the importance and clinical implications of peroxisome proliferator-activated receptor gamma (PPARgamma) signaling in prostate cancer. Journal of Cellular Biochemistry 91 513–527.


Polascik TJ, Oesterling JE & Partin AW 1999 Prostate specific antigen: a decade of discovery – what we have learned and where we are going. Journal of Urology 162 293–306.

Prall OW, Rogen EM, Musgrove EA, Watts CK & Sutherland RL 1998 c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. Molecular and Cellular Biology 18 4499–4508.


